Medisafe 1 Technologies Exhibition Generates Remarkable Interest at HealthAchieve Conference

^{Published on 2010-11-12 13:16:13 - Market Wire}
 

Medisafe 1 Technologies Exhibition Generates Remarkable Interest at HealthAchieve Conference -- JERUSALEM, November 12, 2010 /PRNewswire-FirstCall/ --

JERUSALEM, November 12, 2010 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company's exhibition of its barcoded syringe locking-device generated significant interest at the HealthAchieve Conference November 8-10, in Toronto, Canada.

Over 35 companies responded favorably, including some of the nation's largest medical suppliers, expressing interest in learning more about the potential widespread implementation of the lifesaving device.

A report drawn up by a third-party on Medisafe 1 Technologies' exhibit stated the following, "The overall response was overwhelmingly favorable. The features and benefits of the system were immediately apparent and the spontaneous response was almost always that this is a great product.

HealthAchieve is one of the largest and most prestigious health care gatherings in North America, with over 9,000 health care and business leaders from around the world.

"We are very pleased with the overwhelmingly positive response our exhibition received at the HealthAchieve Conference," said, Jacob Elhadad, CEO of Medisafe 1 Technologies. "This was the first such presentation of our patented syringe locking system. Implementation of the system in hospitals has the potential to significantly reduce the large number of deaths that occur each year due to improper administration of medicines."

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at [ http://www.sec.gov ].

 Contact: Jacob Elhadad CEO +972-524440000 [ Jacob.elhadad10@gmail.com ]

SOURCE Medisafe 1 Technologies Corp.